Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seroquel XR Remission Claims Challenged By FDA As AstraZeneca Puts Lawsuits To Rest

This article was originally published in The Pink Sheet Daily

Executive Summary

"Remission" has no regulatory definition in major depressive disorder, FDA says in letter citing a sales rep aid left with doctors.

You may also be interested in...



AstraZeneca Settles Seroquel Suits For A Third Of What Lilly Paid For Zyprexa

In deciding to settle rather than continue to litigate Seroquel (quetiapine) product liability claims, AstraZeneca is following the path Lilly took in resolving suits over its antipsychotic Zyprexa (olanzapine). But the financial burden won't be as heavy for AstraZeneca

AstraZeneca Settles Seroquel Suits For A Third Of What Lilly Paid For Zyprexa

In deciding to settle rather than continue to litigate Seroquel (quetiapine) product liability claims, AstraZeneca is following the path Lilly took in resolving suits over its antipsychotic Zyprexa (olanzapine). But the financial burden won't be as heavy for AstraZeneca

AstraZeneca's Seroquel Settlement With DoJ Is Fourth Targeting Antipsychotic Off-Label Promotion; Firm Avoids Criminal Charges

AstraZeneca's level of cooperation with the Department of Justice's investigation into allegations of off-label promotion for its antipsychotic Seroquel (quetiapine) may have helped shape the final $520 million civil settlement

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel